Enzalutamide approved for new prostate cancer indication Enzalutamide (Xtandi) has been approved by the TGA for a new indication of metastatic hormone-sensitive prostate cancer (mHSPC). The androgen receptor inhibitor is already indicated as oral therapy for patients with non-metastatic castration resistant PC, metastatic castration-resistant PC. Manufacturer Astellas said enzalutamide was not currently reimbursed under the ...
News in brief: Enzalutamide for mHSPC; Treatment decision help for older cancer patients; Statins linked to endometrial cancer survival
15 Apr 2021